Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 11/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.49 |
| ▸ | ITGAL | P20701 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14305627 | 1.00 | PRKCI (0.55) | PRKCICAPN1CTSSL3MBTL1GPR132 | |
| SCHEMBL13320482 | 0.86 | KLKB1 (0.52) | PRKCICAPN1CTSS | |
| SCHEMBL13352182 | 0.86 | KLKB1 (0.52) | PRKCICAPN1CTSS | |
| SCHEMBL9489744 | 0.82 | L3MBTL1 (0.57) | L3MBTL1CA2CA1 | |
| SCHEMBL4001531 | 0.82 | L3MBTL1 (0.57) | L3MBTL1CA2CA1 | |
| SCHEMBL4001530 | 0.82 | L3MBTL1 (0.57) | L3MBTL1CA2CA1 | |
| SCHEMBL7609992 | 0.80 | ITGB1 (0.73) | ITGB1ITGA4 | |
| SCHEMBL23864379 | 0.79 | L3MBTL1 (0.60) | L3MBTL1CA2CA1 | |
| SCHEMBL16088662 | 0.79 | L3MBTL1 (0.60) | L3MBTL1CA2CA1 | |
| SCHEMBL8337801 | 0.79 | L3MBTL1 (0.60) | L3MBTL1ITGB1ITGA4CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2687533-A2 | Acrylamide derivatives as FAB I inhibitors | Affinium Pharmaceuticals, Inc. (CA) | 2014-01-22 | — | — | EP | disclosed |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-09-12 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2054422-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008009122-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | PRKCI 1125/4885CAPN1 422/4885CTSS 1709/4885 |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | PRKCI 1125/4885CAPN1 422/4885CTSS 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.